Oethmaan Biosims is a South African pharmaceutical company focused on delivering affordable, high quality medicines across both private and public healthcare sectors. As a fully black owned enterprise, the company operates across the pharmaceutical value chain, from product development and regulatory approval to distribution, ensuring consistent access to essential treatments. With strong emphasis on quality and compliance, its products are approved by regulatory authorities and supported by internationally certified manufacturing partners, enabling the company to provide safe and reliable medicines to patients and healthcare providers.
The company places particular focus on biosimilar and generic medicines, aiming to address the rising cost of treating chronic and life threatening conditions such as cancer. By leveraging its own intellectual property portfolio and expanding product pipeline, Oethmaan Biosims continues to grow its presence across South Africa and into broader African markets. Through strategic partnerships, ongoing product development, and a commitment to accessibility, the company strives to improve healthcare outcomes and make essential medicines more affordable for communities in emerging economies.